MARC details
| 000 -LEADER |
|---|
| fixed length control field |
02821nam a22003617a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
221213s20222022 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
2072-6694 |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
10.3390/cancers14205051 [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
cancers14205051 [pii] |
| 024 ## - OTHER STANDARD IDENTIFIER |
|---|
| Standard number or code |
PMC9599862 [pmc] |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
36291835 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
Event-Free Survival in Patients with Early HER2-Positive Breast Cancer with a Pathological Complete Response after HER2-Targeted Therapy: A Pooled Analysis. |
| 251 ## - Source |
|---|
| Source |
Cancers. 14(20), 2022 Oct 15. |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
Cancers (Basel). 14(20), 2022 Oct 15. |
| 253 ## - Journal Name |
|---|
| Journal name |
Cancers |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2022 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2023 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Publication date |
2022 Oct 15 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] |
|---|
| Publication status |
epublish |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2022-12-13 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
The standard-of-care for patients with pathological complete response (pCR) after neoadjuvant human epidermal growth factor receptor 2 (HER2)-targeted therapy plus chemotherapy is continuation of HER2-targeted therapy in the adjuvant setting. Our objective was to evaluate risk of recurrence or death in these patients and determine if outcomes differed by the HER2-targeted regimen received in each setting. We analyzed patient-level data from five randomized trials evaluating trastuzumab, pertuzumab, or both as part of systemic neoadjuvant and adjuvant therapy for HER2-positive early breast cancer, and assessed event-free survival (EFS) in 1763 patients. Patients with pCR had decreased risk of an EFS event versus those with residual disease (unadjusted hazard ratio [HR] = 0.35; 95% confidence interval [CI]: 0.27-0.46). Regardless of pCR status, after adjusting for baseline factors, reduction in EFS event risk was greater in patients administered pertuzumab/trastuzumab in both settings versus those administered only trastuzumab in both settings (HR = 0.36; 95% CI: 0.26-0.49), or pertuzumab/trastuzumab in the neoadjuvant setting and only trastuzumab in the adjuvant setting (HR = 0.67; 95% CI: 0.47-0.96). Patients with pCR had longer EFS than those with residual disease. Patients treated with pertuzumab/trastuzumab in both the neoadjuvant and adjuvant settings had the lowest risk of breast cancer recurrence. |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
IN PROCESS -- NOT YET INDEXED |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
Associate Dean for Research Development |
| 656 ## - INDEX TERM--OCCUPATION |
|---|
| Department |
MedStar Health |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Swain, Sandra M |
| Institution Code |
MSH |
| 790 ## - Authors |
|---|
| All authors |
Cortazar P, Cortes J, Dang C, du Toit Y, Gianni L, Heinzmann D, Hurvitz SA, Jackisch C, Knott A, Macharia H, Schneeweiss A, Slamon D, Song C, Swain SM, Valagussa P |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.3390/cancers14205051">https://dx.doi.org/10.3390/cancers14205051</a> |
| Public note |
https://dx.doi.org/10.3390/cancers14205051 |
| 858 ## - ORCID |
|---|
| ORCID text |
Swain, Sandra M |
| Orcid |
<a href="https://orcid.org/0000-0002-1320-3830">https://orcid.org/0000-0002-1320-3830</a> |
| Name |
https://orcid.org/0000-0002-1320-3830 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
